Beyond antipsychotic efficacy and toward an individualized therapeutic strategy: analysis of the systemic, metabolic, and inflammatory effects of olanzapine, haloperidol, and their combination in schizophrenic patients. [PDF]
Alharbi NS +6 more
europepmc +1 more source
Risk of neutropenia-related hospitalisation among clozapine initiators. [PDF]
Sarpatwari A +13 more
europepmc +1 more source
Comparison of Antipsychotics in the Treatment of COVID-19-Induced First-Episode Psychosis: A Review of Case Studies. [PDF]
Singh G +6 more
europepmc +1 more source
Low-dose olanzapine for cancer-associated anorexia and nausea: insights from clinical practice. [PDF]
Biswas R, Choudhury KB, Halder A.
europepmc +1 more source
Population Pharmacokinetic Model-Based Dose Selection of Extended-Release Injectable Olanzapine (TV-44749) for Subcutaneous Use in Phase 3 Clinical Trial in Adults with Schizophrenia. [PDF]
Perlstein I +6 more
europepmc +1 more source
Effect of antipsychotic consumption during pregnancy on risk of gestational diabetes development: a systematic review and meta-analysis. [PDF]
Liu J, Zhao Y.
europepmc +1 more source
Olanzapine affects bone formation via oral <i>Enterococcus</i> through <i>SAA1</i> gene and extracellular matrix-related pathways. [PDF]
Yuan H +18 more
europepmc +1 more source
The effect of olanzapine on lipid profiles in humans: a time and dose response meta-analysis of randomized controlled trials. [PDF]
Fang Z +4 more
europepmc +1 more source
Antipsychotic load during olanzapine mono- versus polytherapy and in relation to age. [PDF]
Solhaug V +6 more
europepmc +1 more source
Olanzapine Plus Triple Antiemetic Therapy for the Prevention of Platinum-Based Delayed-Phase Chemotherapy-Induced Nausea and Vomiting: A Meta-Analysis. [PDF]
Gong W +5 more
europepmc +1 more source

